Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

Discover what every stage of breast cancer means for treatment options and recovery, with expert insights to help navigate a ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy. Lerociclib plus fulvestrant demonstrated a ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Research from Weill Cornell Medicine has identified a molecular pathway linking omega-6 linoleic acid—a common dietary fat in ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

Discover Celcuity's Q4 2024 insights: gedatolisib's promising trials for breast cancer, $2B market potential, and key 2025 milestones.

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.